CG ONCOLOGY, INC. COMMON STOCK
NASDAQ: CGON (CG Oncology, Inc.)
Last update: 4 hours ago73.43
7.09 (10.69%)
| Previous Close | 66.34 |
| Open | 67.61 |
| Volume | 1,765,233 |
| Avg. Volume (3M) | 1,272,762 |
| Market Cap | 6,200,076,800 |
| Price / Sales | 1.29 |
| Price / Book | 7.55 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Operating Margin (TTM) | -81,161.54% |
| Diluted EPS (TTM) | -1.50 |
| Quarterly Revenue Growth (YOY) | -90.20% |
| Total Debt/Equity (MRQ) | 0.15% |
| Current Ratio (MRQ) | 30.97 |
| Operating Cash Flow (TTM) | -81.98 M |
| Levered Free Cash Flow (TTM) | -57.18 M |
| Return on Assets (TTM) | -12.85% |
| Return on Equity (TTM) | -16.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | CG Oncology, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.75 |
|
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.17% |
| % Held by Institutions | 105.34% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Decheng Capital Llc | 31 Dec 2025 | 6,371,669 |
| Tcg Crossover Management, Llc | 31 Dec 2025 | 3,670,206 |
| Foresite Capital Management Vi Llc | 31 Dec 2025 | 2,221,474 |
| Braidwell Lp | 31 Dec 2025 | 1,870,571 |
| Orbimed Advisors Llc | 31 Dec 2025 | 1,516,550 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (HC Wainwright & Co., 8.95%) | Buy |
| Median | 75.00 (2.14%) | |
| Low | 73.00 (RBC Capital, -0.59%) | Buy |
| Average | 76.00 (3.50%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 56.34 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 27 Feb 2026 | 80.00 (8.95%) | Buy | 58.80 |
| Truist Securities | 10 Feb 2026 | 75.00 (2.14%) | Buy | 53.09 |
| RBC Capital | 21 Jan 2026 | 73.00 (-0.59%) | Buy | 57.13 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |